Cue Biopharma Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Cue Biopharma's estimated annual revenue is currently $9.6M per year.(i)
  • Cue Biopharma's estimated revenue per employee is $155,000

Employee Data

  • Cue Biopharma has 62 Employees.(i)
  • Cue Biopharma grew their employee count by 11% last year.

Cue Biopharma's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$43.6M21719%N/AN/A
Add Company

What Is Cue Biopharma?

Cue Biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers, autoimmune disorders and infectious diseases. We design biologics to engage and modulate the activity of antigen-specific T cells in the patient's body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. We believe our biologics allow us to target antigen-specific T cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the Cue Biologics Platform. This flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. Headquartered in Kendall Square, Cambridge, MA, we are led by an experienced management team and scientific and clinical advisory board (SAB/CAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

keywords:N/A

N/A

Total Funding

62

Number of Employees

$9.6M

Revenue (est)

11%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Cue Biopharma News

2022-04-20 - Cue Biopharma, Inc. (NASDAQ:CUE) Given Consensus ...

Cue Biopharma, Inc. (NASDAQ:CUE) Given Consensus Rating of “Buy” by Analysts. Posted by admin on Apr 23rd, 2022. Share on Twitter Share on Facebook Share on...

2022-04-17 - Cue Biopharma, Inc. (NASDAQ:CUE) Expected to Announce ...

Two analysts have issued estimates for Cue Biopharma's earnings, with the lowest sales estimate coming in at $2.00 million and the highest...

2022-04-17 - Cue Biopharma, Inc. (NASDAQ:CUE) Expected to Post ...

Two analysts have provided estimates for Cue Biopharma's earnings, with the lowest EPS estimate coming in at ($0.45) and the highest estimate...

2021-09-28 - Cue Biopharma : Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT and Neo-STAT

Research demonstrates that platform technologies generate therapeutic molecules for selective delivery of immune activating signals, such as IL-2, to disease-relevant T cells, hence avoiding systemic activation of the broader immune compartment Publication details the peptide-HLA-based platform’ ...

2017-01-24 - Cue Biopharma Raises $26M in Funding

Cue Biopharma, Inc., a Cambridge, MA-based immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, raised $26m in funding. The round was led by MDB Capital Group. The company will use the proceeds to ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.4M622%N/A
#2
$6.2M62-13%$496.2M
#3
$18M62-3%N/A
#4
$11.7M6238%N/A
#5
$3.5M6222%N/A